{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:29:26Z","timestamp":1790728166237,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T00:00:00Z","timestamp":1759881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01CA249949"],"award-info":[{"award-number":["R01CA249949"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000738","name":"U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["1IK6BX003787"],"award-info":[{"award-number":["1IK6BX003787"]}],"id":[{"id":"10.13039\/100000738","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Exp Clin Cancer Res"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Gastric carcinoma ranks as the fifth most common cause of cancer-related mortality globally. Chemoresistance remains a critical barrier to treatment efficacy, driving poor survival outcomes in gastric cancer patients. Cyclin-dependent kinase 1 (CDK1) is overexpressed in several malignancies. SOX9 transcription factor plays critical roles in gastric tumorigenesis and therapeutic resistance. This study identifies a CDK1-SOX9-BCL-xL signaling axis as an important mediator of chemoresistance in gastric cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Bioinformatics and computational approaches were used for analysis of human and mouse public and local data sets. Chromatin immunoprecipitation (ChIP), western blotting, quantitative PCR (qPCR), immunofluorescence, and immunohistochemistry assays were applied in the study. The study utilized a number of in vitro models including cell lines and patient-derived tumoroids. The in vivo models included patient-derived xenograft (PDX), the <jats:italic>Tff1<\/jats:italic> knockout, and <jats:italic>Cdk1<\/jats:italic> conditional knockout mouse models.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Our study identified concurrent overexpression of CDK1 and SOX9 in gastric cancer patients. Genetic knockdown and pharmacological inhibition of CDK1 suppressed SOX9 protein levels and transcriptional activity in vitro and in vivo. Mechanistically, CDK1 regulates SOX9 through a miR-145-dependent epigenetic axis: CDK1-mediated phosphorylation and activation of DNMT1 to drive methylation-dependent silencing of miR-145, thereby relieving miR-145\u2019s repression of SOX9. Strikingly, both CDK1 and SOX9 were upregulated in cisplatin-resistant gastric cancer cell lines. We further identified BCL-xL as a direct transcriptional target of SOX9, functionally mediating cisplatin resistance. CDK1 inhibition using dinaciclib re-sensitized resistant models to cisplatin by disrupting the CDK1-SOX9-BCL-xL pathway, underscoring its central role in chemoresistance. In PDX models, combining dinaciclib with cisplatin synergistically reduced tumor volume, and extended survival compared to monotherapies, highlighting the therapeutic potential.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>This study elucidates the epigenetic and transcriptional mechanisms driving the CDK1-SOX9-BCL-xL axis in gastric cancer chemoresistance. Pharmacological inhibition of CDK1 effectively disrupts this axis, restoring cisplatin sensitivity and suppressing tumor growth in gastric cancer models. The observed synergy between dinaciclib and cisplatin underscores a promising therapeutic strategy to overcome chemoresistance in gastric cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Graphical abstract<\/jats:title>\n          <\/jats:sec>","DOI":"10.1186\/s13046-025-03523-3","type":"journal-article","created":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T09:04:57Z","timestamp":1759914297000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["CDK1 drives SOX9-mediated chemotherapeutic resistance in gastric cancer"],"prefix":"10.1186","volume":"44","author":[{"given":"Marwah","family":"Al-Mathkour","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julio","family":"Poveda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Longlong","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver G.","family":"McDonald","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dunfa","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Soutto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhibin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shria","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander","family":"Zaika","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Giordano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoumin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"El-Rifai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,8]]},"reference":[{"key":"3523_CR1","doi-asserted-by":"crossref","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. 2024;74(3):229\u201363.","DOI":"10.3322\/caac.21834"},{"issue":"1","key":"3523_CR2","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13045-023-01451-3","volume":"16","author":"WL Guan","year":"2023","unstructured":"Guan WL, He Y, Xu RH. Gastric cancer treatment: recent progress and future perspectives. J Hematol Oncol. 2023;16(1):57.","journal-title":"J Hematol Oncol"},{"issue":"3","key":"3523_CR3","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/S0165-6147(03)00026-9","volume":"24","author":"ZA Stewart","year":"2003","unstructured":"Stewart ZA, Westfall MD, Pietenpol JA. Cell-cycle dysregulation and anticancer therapy. Trends Pharmacol Sci. 2003;24(3):139\u201345.","journal-title":"Trends Pharmacol Sci"},{"issue":"7","key":"3523_CR4","doi-asserted-by":"publisher","first-page":"758","DOI":"10.2174\/1871520620666200203125712","volume":"20","author":"S Izadi","year":"2020","unstructured":"Izadi S, Nikkhoo A, Hojjat-Farsangi M, Namdar A, Azizi G, Mohammadi H, et al. CDK1 in breast cancer: implications for theranostic potential. Anticancer Agents Med Chem. 2020;20(7):758\u201367.","journal-title":"Anticancer Agents Med Chem"},{"issue":"9","key":"3523_CR5","doi-asserted-by":"publisher","first-page":"1743","DOI":"10.1007\/s12094-021-02575-z","volume":"23","author":"Z Huang","year":"2021","unstructured":"Huang Z, Shen G, Gao J. CDK1 promotes the stemness of lung cancer cells through interacting with Sox2. Clin Transl Oncol. 2021;23(9):1743\u201351.","journal-title":"Clin Transl Oncol"},{"issue":"23","key":"3523_CR6","doi-asserted-by":"publisher","first-page":"6561","DOI":"10.1158\/0008-5472.CAN-18-0330","volume":"78","author":"D Ravindran Menon","year":"2018","unstructured":"Ravindran Menon D, Luo Y, Arcaroli JJ, Liu S, KrishnanKutty LN, Osborne DG, et al. CDK1 interacts with Sox2 and promotes tumor initiation in human melanoma. Cancer Res. 2018;78(23):6561\u201374.","journal-title":"Cancer Res"},{"issue":"1","key":"3523_CR7","doi-asserted-by":"publisher","first-page":"112005","DOI":"10.1016\/j.celrep.2023.112005","volume":"42","author":"S Zhu","year":"2023","unstructured":"Zhu S, Al-Mathkour M, Cao L, Khalafi S, Chen Z, Poveda J, et al. CDK1 bridges NF-kappaB and beta-catenin signaling in response to H. pylori infection in gastric tumorigenesis. Cell Rep. 2023;42(1):112005.","journal-title":"Cell Rep"},{"issue":"9","key":"3523_CR8","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s12032-022-01748-2","volume":"39","author":"S Sofi","year":"2022","unstructured":"Sofi S, Mehraj U, Qayoom H, Aisha S, Almilaibary A, Alkhanani M, et al. Targeting cyclin-dependent kinase 1 (CDK1) in cancer: molecular Docking and dynamic simulations of potential CDK1 inhibitors. Med Oncol. 2022;39(9):133.","journal-title":"Med Oncol"},{"issue":"1","key":"3523_CR9","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s13578-023-01118-z","volume":"13","author":"X Xu","year":"2023","unstructured":"Xu X, Ding Y, Jin J, Xu C, Hu W, Wu S, et al. Post-translational modification of CDK1-STAT3 signaling by Fisetin suppresses pancreatic cancer stem cell properties. Cell Biosci. 2023;13(1):176.","journal-title":"Cell Biosci"},{"issue":"3","key":"3523_CR10","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1007\/s00428-012-1201-7","volume":"460","author":"M Sun","year":"2012","unstructured":"Sun M, Uozaki H, Hino R, Kunita A, Shinozaki A, Ushiku T, et al. SOX9 expression and its methylation status in gastric cancer. Virchows Arch. 2012;460(3):271\u20139.","journal-title":"Virchows Arch"},{"issue":"7","key":"3523_CR11","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1053\/j.gastro.2023.03.215","volume":"164","author":"HYG Lim","year":"2023","unstructured":"Lim HYG, Barker N. Sox9, A key regulator of gastric stem cell behavior driving cancer initiation. Gastroenterology. 2023;164(7):1052\u20133.","journal-title":"Gastroenterology"},{"issue":"2","key":"3523_CR12","doi-asserted-by":"publisher","first-page":"188517","DOI":"10.1016\/j.bbcan.2021.188517","volume":"1875","author":"M Panda","year":"2021","unstructured":"Panda M, Tripathi SK, Biswal BK. SOX9: an emerging driving factor from cancer progression to drug resistance. Biochim Biophys Acta Rev Cancer. 2021;1875(2):188517.","journal-title":"Biochim Biophys Acta Rev Cancer"},{"issue":"1","key":"3523_CR13","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/hep.28509","volume":"64","author":"C Liu","year":"2016","unstructured":"Liu C, Liu L, Chen X, Cheng J, Zhang H, Shen J, et al. Sox9 regulates self-renewal and tumorigenicity by promoting symmetrical cell division of cancer stem cells in hepatocellular carcinoma. Hepatology. 2016;64(1):117\u201329.","journal-title":"Hepatology"},{"key":"3523_CR14","doi-asserted-by":"publisher","first-page":"402","DOI":"10.3389\/fendo.2018.00402","volume":"9","author":"J O\u2019Brien","year":"2018","unstructured":"O\u2019Brien J, Hayder H, Zayed Y, Peng C. Overview of MicroRNA biogenesis, mechanisms of actions, and circulation. Front Endocrinol (Lausanne). 2018;9:402.","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"11","key":"3523_CR15","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1002\/cncr.28002","volume":"119","author":"Z Chen","year":"2013","unstructured":"Chen Z, Saad R, Jia P, Peng D, Zhu S, Washington MK, et al. Gastric adenocarcinoma has a unique MicroRNA signature not present in esophageal adenocarcinoma. Cancer. 2013;119(11):1985\u201393.","journal-title":"Cancer"},{"key":"3523_CR16","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.2147\/OTT.S72457","volume":"8","author":"D Zhu","year":"2015","unstructured":"Zhu D, Chen H, Yang X, Chen W, Wang L, Xu J, et al. miR-32 functions as a tumor suppressor and directly targets SOX9 in human non-small cell lung cancer. Onco Targets Ther. 2015;8:1773\u201383.","journal-title":"Onco Targets Ther"},{"issue":"6","key":"3523_CR17","doi-asserted-by":"publisher","first-page":"4155","DOI":"10.3892\/ol.2017.5964","volume":"13","author":"Y Guo","year":"2017","unstructured":"Guo Y, Qi Y, Guo A, Du C, Zhang R, Chu X. miR-564 is downregulated in gastric carcinoma and targets E2F3. Oncol Lett. 2017;13(6):4155\u201360.","journal-title":"Oncol Lett"},{"issue":"4","key":"3523_CR18","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1053\/j.gastro.2018.11.052","volume":"156","author":"Z Chen","year":"2019","unstructured":"Chen Z, Li Z, Soutto M, Wang W, Piazuelo MB, Zhu S, et al. Integrated analysis of mouse and human gastric neoplasms identifies conserved MicroRNA networks in gastric carcinogenesis. Gastroenterology. 2019;156(4):1127\u2013e398.","journal-title":"Gastroenterology"},{"issue":"5378","key":"3523_CR19","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1126\/science.281.5378.838","volume":"281","author":"AA Fienberg","year":"1998","unstructured":"Fienberg AA, Hiroi N, Mermelstein PG, Song W, Snyder GL, Nishi A, et al. DARPP-32: regulator of the efficacy of dopaminergic neurotransmission. Science. 1998;281(5378):838\u201342.","journal-title":"Science"},{"issue":"6","key":"3523_CR20","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1002\/dvg.20397","volume":"46","author":"AL Means","year":"2008","unstructured":"Means AL, Xu Y, Zhao A, Ray KC, Gu G. A CK19(CreERT) knockin mouse line allows for conditional DNA recombination in epithelial cells in multiple endodermal organs. Genesis. 2008;46(6):318\u201323.","journal-title":"Genesis"},{"issue":"5","key":"3523_CR21","doi-asserted-by":"publisher","first-page":"1753","DOI":"10.1172\/JCI43922","volume":"121","author":"M Soutto","year":"2011","unstructured":"Soutto M, Belkhiri A, Piazuelo MB, Schneider BG, Peng D, Jiang A, et al. Loss of TFF1 is associated with activation of NF-kappaB-mediated inflammation and gastric neoplasia in mice and humans. J Clin Invest. 2011;121(5):1753\u201367.","journal-title":"J Clin Invest"},{"issue":"5285","key":"3523_CR22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1126\/science.274.5285.259","volume":"274","author":"O Lefebvre","year":"1996","unstructured":"Lefebvre O, Chenard MP, Masson R, Linares J, Dierich A, LeMeur M, et al. Gastric mucosa abnormalities and tumorigenesis in mice lacking the pS2 trefoil protein. Science. 1996;274(5285):259\u201362.","journal-title":"Science"},{"key":"3523_CR23","doi-asserted-by":"crossref","unstructured":"Okada S, Vaeteewoottacharn K, Kariya R. Application of highly immunocompromised mice for the establishment of Patient-Derived xenograft (PDX) models. Cells. 2019;8(8).","DOI":"10.3390\/cells8080889"},{"issue":"5142","key":"3523_CR24","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1126\/science.8266103","volume":"262","author":"S van den Heuvel","year":"1993","unstructured":"van den Heuvel S, Harlow E. Distinct roles for cyclin-dependent kinases in cell cycle control. Science. 1993;262(5142):2050\u20134.","journal-title":"Science"},{"issue":"7414","key":"3523_CR25","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/nature11247","volume":"489","author":"An integrated encyclopedia","year":"2012","unstructured":"An integrated encyclopedia. Of DNA elements in the human genome. Nature. 2012;489(7414):57\u201374.","journal-title":"Nature"},{"issue":"43","key":"3523_CR26","doi-asserted-by":"publisher","first-page":"15545","DOI":"10.1073\/pnas.0506580102","volume":"102","author":"A Subramanian","year":"2005","unstructured":"Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102(43):15545\u201350.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"3523_CR27","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.cell.2018.03.034","volume":"173","author":"TM Malta","year":"2018","unstructured":"Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, et al. Machine learning identifies stemness features associated with oncogenic dedifferentiation. Cell. 2018;173(2):338\u201354. e15.","journal-title":"Cell"},{"issue":"7","key":"3523_CR28","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.1053\/j.gastro.2023.01.037","volume":"164","author":"Q Chen","year":"2023","unstructured":"Chen Q, Weng K, Lin M, Jiang M, Fang Y, Chung SSW, et al. SOX9 modulates the transformation of gastric stem cells through biased symmetric cell division. Gastroenterology. 2023;164(7):1119\u2013e3612.","journal-title":"Gastroenterology"},{"issue":"7031","key":"3523_CR29","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nature03441","volume":"434","author":"X Xie","year":"2005","unstructured":"Xie X, Lu J, Kulbokas EJ, Golub TR, Mootha V, Lindblad-Toh K, et al. Systematic discovery of regulatory motifs in human promoters and 3\u2019 UTRs by comparison of several mammals. Nature. 2005;434(7031):338\u201345.","journal-title":"Nature"},{"issue":"57","key":"3523_CR30","doi-asserted-by":"publisher","first-page":"7180","DOI":"10.1038\/onc.2008.327","volume":"27","author":"EM Schaeffer","year":"2008","unstructured":"Schaeffer EM, Marchionni L, Huang Z, Simons B, Blackman A, Yu W, et al. Androgen-induced programs for prostate epithelial growth and invasion arise in embryogenesis and are reactivated in cancer. Oncogene. 2008;27(57):7180\u201391.","journal-title":"Oncogene"},{"issue":"5","key":"3523_CR31","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1021\/ml100051d","volume":"1","author":"K Paruch","year":"2010","unstructured":"Paruch K, Dwyer MP, Alvarez C, Brown C, Chan TY, Doll RJ, et al. Discovery of Dinaciclib (SCH 727965): A potent and selective inhibitor of Cyclin-Dependent kinases. ACS Med Chem Lett. 2010;1(5):204\u20138.","journal-title":"ACS Med Chem Lett"},{"issue":"Database issue","key":"3523_CR32","doi-asserted-by":"publisher","first-page":"D91","DOI":"10.1093\/nar\/gkh012","volume":"32","author":"A Sandelin","year":"2004","unstructured":"Sandelin A, Alkema W, Engstrom P, Wasserman WW, Lenhard B. JASPAR: an open-access database for eukaryotic transcription factor binding profiles. Nucleic Acids Res. 2004;32(Database issue):D91\u20134.","journal-title":"Nucleic Acids Res"},{"issue":"3","key":"3523_CR33","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"3523_CR34","doi-asserted-by":"crossref","unstructured":"Ham A, Cho MH, Won HS, Jo J, Lee KE. beta\u2013catenin blockers enhance the effect of CDK4\/6 inhibitors on stemness and proliferation suppression in endocrine\u2013resistant breast cancer cells. Oncol Rep. 2022;48(1).","DOI":"10.3892\/or.2022.8341"},{"key":"3523_CR35","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/bs.acr.2018.12.002","volume":"141","author":"S Talukdar","year":"2019","unstructured":"Talukdar S, Bhoopathi P, Emdad L, Das S, Sarkar D, Fisher PB. Dormancy and cancer stem cells: an enigma for cancer therapeutic targeting. Adv Cancer Res. 2019;141:43\u201384.","journal-title":"Adv Cancer Res"},{"key":"3523_CR36","doi-asserted-by":"publisher","first-page":"960317","DOI":"10.3389\/fonc.2022.960317","volume":"12","author":"CM Tilsed","year":"2022","unstructured":"Tilsed CM, Fisher SA, Nowak AK, Lake RA, Lesterhuis WJ. Cancer chemotherapy: insights into cellular and tumor microenvironmental mechanisms of action. Front Oncol. 2022;12:960317.","journal-title":"Front Oncol"},{"key":"3523_CR37","doi-asserted-by":"publisher","first-page":"6754040","DOI":"10.1155\/2019\/6754040","volume":"2019","author":"M Aguilar-Medina","year":"2019","unstructured":"Aguilar-Medina M, Avendano-Felix M, Lizarraga-Verdugo E, Bermudez M, Romero-Quintana JG, Ramos-Payan R, et al. SOX9 Stem-Cell factor: clinical and functional relevance in cancer. J Oncol. 2019;2019:6754040.","journal-title":"J Oncol"},{"issue":"1","key":"3523_CR38","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.stem.2015.05.008","volume":"17","author":"JC Larsimont","year":"2015","unstructured":"Larsimont JC, Youssef KK, Sanchez-Danes A, Sukumaran V, Defrance M, Delatte B, et al. Sox9 controls Self-Renewal of oncogene targeted cells and links tumor initiation and invasion. Cell Stem Cell. 2015;17(1):60\u201373.","journal-title":"Cell Stem Cell"},{"key":"3523_CR39","doi-asserted-by":"publisher","first-page":"30489","DOI":"10.1038\/srep30489","volume":"6","author":"T Kawai","year":"2016","unstructured":"Kawai T, Yasuchika K, Ishii T, Miyauchi Y, Kojima H, Yamaoka R, et al. SOX9 is a novel cancer stem cell marker surrogated by osteopontin in human hepatocellular carcinoma. Sci Rep. 2016;6:30489.","journal-title":"Sci Rep"},{"issue":"5","key":"3523_CR40","doi-asserted-by":"publisher","first-page":"3115","DOI":"10.3892\/or.2016.4648","volume":"35","author":"X Wang","year":"2016","unstructured":"Wang X, Liu Y, Liu X, Yang J, Teng G, Zhang L, et al. MiR-124 inhibits cell proliferation, migration and invasion by directly targeting SOX9 in lung adenocarcinoma. Oncol Rep. 2016;35(5):3115\u201321.","journal-title":"Oncol Rep"},{"issue":"2","key":"3523_CR41","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1007\/s11010-022-04507-z","volume":"478","author":"TY Chao","year":"2023","unstructured":"Chao TY, Kordass T, Osen W, Eichmuller SB. SOX9 is a target of miR-134-3p and miR-224-3p in breast cancer cell lines. Mol Cell Biochem. 2023;478(2):305\u201315.","journal-title":"Mol Cell Biochem"},{"issue":"1","key":"3523_CR42","doi-asserted-by":"publisher","first-page":"3039","DOI":"10.1038\/s41467-019-11011-4","volume":"10","author":"M Soutto","year":"2019","unstructured":"Soutto M, Chen Z, Bhat AA, Wang L, Zhu S, Gomaa A, et al. Activation of STAT3 signaling is mediated by TFF1 Silencing in gastric neoplasia. Nat Commun. 2019;10(1):3039.","journal-title":"Nat Commun"},{"key":"3523_CR43","doi-asserted-by":"publisher","first-page":"985363","DOI":"10.3389\/fonc.2022.985363","volume":"12","author":"S Qian","year":"2022","unstructured":"Qian S, Wei Z, Yang W, Huang J, Yang Y, Wang J. The role of BCL-2 family proteins in regulating apoptosis and cancer therapy. Front Oncol. 2022;12:985363.","journal-title":"Front Oncol"},{"key":"3523_CR44","doi-asserted-by":"publisher","first-page":"1067207","DOI":"10.3389\/fmolb.2022.1067207","volume":"9","author":"K Harada","year":"2022","unstructured":"Harada K, Sakamoto N. Cancer organoid applications to investigate chemotherapy resistance. Front Mol Biosci. 2022;9:1067207.","journal-title":"Front Mol Biosci"},{"issue":"6","key":"3523_CR45","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1111\/cts.12802","volume":"13","author":"AG Murphy","year":"2020","unstructured":"Murphy AG, Zahurak M, Shah M, Weekes CD, Hansen A, Siu LL, et al. A phase I study of Dinaciclib in combination with MK-2206 in patients with advanced pancreatic cancer. Clin Transl Sci. 2020;13(6):1178\u201388.","journal-title":"Clin Transl Sci"},{"issue":"4","key":"3523_CR46","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1182\/bloodadvances.2021005872","volume":"6","author":"GP Gregory","year":"2022","unstructured":"Gregory GP, Kumar S, Wang D, Mahadevan D, Walker P, Wagner-Johnston N, et al. Pembrolizumab plus Dinaciclib in patients with hematologic malignancies: the phase 1b KEYNOTE-155 study. Blood Adv. 2022;6(4):1232\u201342.","journal-title":"Blood Adv"}],"container-title":["Journal of Experimental &amp; Clinical Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03523-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13046-025-03523-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13046-025-03523-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T10:04:28Z","timestamp":1759917868000},"score":1,"resource":{"primary":{"URL":"https:\/\/jeccr.biomedcentral.com\/articles\/10.1186\/s13046-025-03523-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,8]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["3523"],"URL":"https:\/\/doi.org\/10.1186\/s13046-025-03523-3","relation":{},"ISSN":["1756-9966"],"issn-type":[{"value":"1756-9966","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,8]]},"assertion":[{"value":"13 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The use of de-identified human data or tissues was identified as non-human subjects research in accordance with the National Institutes of Health guidelines and the University of Miami Institutional Review Board. All animal studies were carried out following the approved protocol by the Institutional Animal Care and Use Committee of the University of Miami (UM-23-110).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not commissioned, externally peer reviewed.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Provenance and peer review"}}],"article-number":"284"}}